CA3072175A1 - Photoreceptor gene modulator photoregulin 3 for treatment of retinal disease - Google Patents

Photoreceptor gene modulator photoregulin 3 for treatment of retinal disease Download PDF

Info

Publication number
CA3072175A1
CA3072175A1 CA3072175A CA3072175A CA3072175A1 CA 3072175 A1 CA3072175 A1 CA 3072175A1 CA 3072175 A CA3072175 A CA 3072175A CA 3072175 A CA3072175 A CA 3072175A CA 3072175 A1 CA3072175 A1 CA 3072175A1
Authority
CA
Canada
Prior art keywords
retina
retinal
subject
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3072175A
Other languages
English (en)
French (fr)
Inventor
Thomas A. Reh
Paul NAKAMURA
Andy SHIMCHUK
Shibing TANG
Sheng Ding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
J David Gladstone Institutes
Original Assignee
University of Washington
J David Gladstone Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, J David Gladstone Institutes filed Critical University of Washington
Publication of CA3072175A1 publication Critical patent/CA3072175A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3072175A 2017-08-10 2018-08-10 Photoreceptor gene modulator photoregulin 3 for treatment of retinal disease Abandoned CA3072175A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762543782P 2017-08-10 2017-08-10
US62/543,782 2017-08-10
PCT/US2018/046272 WO2019032999A1 (en) 2017-08-10 2018-08-10 PHOTORECEPTOR GENE MODULATOR PHOTOREGULIN 3 FOR THE TREATMENT OF RETINAL DISEASE

Publications (1)

Publication Number Publication Date
CA3072175A1 true CA3072175A1 (en) 2019-02-14

Family

ID=65272549

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3072175A Abandoned CA3072175A1 (en) 2017-08-10 2018-08-10 Photoreceptor gene modulator photoregulin 3 for treatment of retinal disease

Country Status (8)

Country Link
US (1) US20200368234A1 (enExample)
EP (1) EP3664801A4 (enExample)
JP (1) JP2020530459A (enExample)
CN (1) CN111093657A (enExample)
AU (1) AU2018313990A1 (enExample)
CA (1) CA3072175A1 (enExample)
MX (1) MX2020001274A (enExample)
WO (1) WO2019032999A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855314B2 (en) * 2013-03-01 2018-01-02 The Schepens Eye Research Insititute, Inc. Methods for modulating development and function of photoreceptor cells
WO2016160718A1 (en) * 2015-03-27 2016-10-06 University Of Washington Methods for treatment of retinal disease by photoreceptor gene expression modulation
CN105343107A (zh) * 2015-12-03 2016-02-24 上海中医药大学附属岳阳中西医结合医院 雷公藤红素在制备防治视网膜退行性改变相关疾病药物中的应用

Also Published As

Publication number Publication date
CN111093657A (zh) 2020-05-01
EP3664801A4 (en) 2021-06-23
JP2020530459A (ja) 2020-10-22
MX2020001274A (es) 2020-09-22
AU2018313990A1 (en) 2020-02-27
US20200368234A1 (en) 2020-11-26
EP3664801A1 (en) 2020-06-17
WO2019032999A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
Kole et al. Activating transcription factor 3 (ATF3) protects retinal ganglion cells and promotes functional preservation after optic nerve crush
Roberti et al. Nerve growth factor modulation of retinal ganglion cell physiology
US10849904B2 (en) Methods for treatment of retinal disease by photoreceptor gene expression modulation
Liu et al. Prolyl-4-hydroxylases inhibitor stabilizes HIF-1α and increases mitophagy to reduce cell death after experimental retinal detachment
Zhang et al. nNOS–CAPON interaction mediates amyloid‐β‐induced neurotoxicity, especially in the early stages
US20250057868A1 (en) Compositions and methods of modulating hif-2a to improve muscle generation and repair
Nakamura et al. Modulation of both intrinsic and extrinsic factors additively promotes rewiring of corticospinal circuits after spinal cord injury
US20250082688A1 (en) Compositions and methods for williams syndrome (ws) therapy
Feng et al. Trilobatin attenuates cerebral ischaemia/reperfusion‐induced blood–brain barrier dysfunction by targeting matrix metalloproteinase 9: The legend of a food additive
Fontainhas et al. RhoA inactivation prevents photoreceptor axon retraction in an in vitro model of acute retinal detachment
Bessero et al. Role of the c‐Jun N‐terminal kinase pathway in retinal excitotoxicity, and neuroprotection by its inhibition
US12233063B2 (en) Compositions and methods for treating eye disorders
US20200368234A1 (en) Photoreceptor gene modulator photoregulin 3 for treatment of retinal disease
BR112021003189A2 (pt) métodos e composições de fármacos para tratar doenças oftálmicas
AU2928199A (en) Method for the treatment of diseases or disorders of the inner ear
Jiang et al. Phosphorylated S6K1 and 4E-BP1 play different roles in constitutively active Rheb-mediated retinal ganglion cell survival and axon regeneration after optic nerve injury
JP2007529555A (ja) シヌクレイノパチーを治療する方法
Loh et al. Melatonin regulation of phase separation in Neuro-PASC: out-maneuvering Janus-faced amyloids
US9987242B2 (en) Treatment of Levodopa-induced Dyskinesias
Batsuuri et al. Targeting Connexin 43 in Retinal Astrocytes Promotes Neuronal Survival in Glaucomatous Injury
Zhao et al. Neuron‐glial cell communication in the traumatic stress‐induced immunomodulation
JP7138934B2 (ja) 網膜神経保護作用を有するアペリン受容体アゴニストを含有する医薬組成物
Ke et al. Autophagy-Induced Microglial Death Contributes to Neuroinflammation in Acute Optic Nerve Injury
US20230390283A1 (en) Uses of chk2 inhibitors
US20220041667A1 (en) Targeting of makap-pde4d3 complexes in neurodegenerative disease

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240212